FATE (Fate Therapeutics) Shiller PE Ratio: (As of Aug. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FATE Fate Therapeutics Inc FATE
33 GF Score
Price $2.44
GF Value $0.77
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Fate Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Fate Therapeutics  (NAS:FATE) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Fate Therapeutics Shiller PE Ratio Related Terms


Fate Therapeutics Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Fate Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fate Therapeutics Shiller PE Ratio Chart

Fate Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Fate Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FATE vs IMRX, NWBO, FHTX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Fate Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fate Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Fate Therapeutics's Shiller PE Ratio falls into.


FATE
33GF Score
Fate Therapeutics Inc FATE
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fate Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Fate Therapeutics's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Fate Therapeutics's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.25/333.9520*333.9520
=-0.250

Current CPI (Jun. 2026) = 333.9520.

Fate Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -0.270 241.428 -0.373
201612 -0.210 241.432 -0.290
201703 -0.240 243.801 -0.329
201706 -0.230 244.955 -0.314
201709 -0.260 246.819 -0.352
201712 -0.290 246.524 -0.393
201803 -0.270 249.554 -0.361
201806 -0.370 251.989 -0.490
201809 -0.310 252.439 -0.410
201812 -0.250 251.233 -0.332
201903 -0.300 254.202 -0.394
201906 -0.360 256.143 -0.469
201909 -0.400 256.759 -0.520
201912 -0.370 256.974 -0.481
202003 -0.440 258.115 -0.569
202006 -0.350 257.797 -0.453
202009 -0.680 260.280 -0.872
202012 -0.610 260.474 -0.782
202103 -0.480 264.877 -0.605
202106 -0.580 271.696 -0.713
202109 -0.450 274.310 -0.548
202112 -0.720 278.802 -0.862
202203 -0.680 287.504 -0.790
202206 -0.790 296.311 -0.890
202209 -0.860 296.808 -0.968
202212 -0.580 296.797 -0.653
202303 -0.190 301.836 -0.210
202306 -0.540 305.109 -0.591
202309 -0.460 307.789 -0.499
202312 -0.450 306.746 -0.490
202403 -0.470 312.332 -0.503
202406 -0.330 314.175 -0.351
202409 -0.400 315.301 -0.424
202412 -0.440 315.605 -0.466
202503 -0.320 319.799 -0.334
202506 -0.290 322.561 -0.300
202509 -0.270 324.800 -0.278
202512 -0.270 324.054 -0.278
202603 -0.260 330.213 -0.263
202606 -0.250 333.952 -0.250

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Fate Therapeutics (FATE) Overvalued in 2026?

Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued. The current stock price of $2.44 is trading 216.9% above its estimated GF Value™ of $0.77. GuruFocus considers Fate Therapeutics to be Significantly Overvalued.

Key valuation signals for FATE:

  • Shiller PE Ratio:
  • GF Value™: $0.77 vs. price of $2.44 (216.9% above fair value)
  • GF Score™: 33/100 with 7 warning signs

No single metric tells the full story. See the FATE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fate Therapeutics Business Description

Other Exchanges F6T:Germany
Address 12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score

Get the complete analysis for FATE

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.44
Price
$0.77
GF Value